The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

Chaccour, CarlosRuiz Castillo, PaulaRichardson, Mary-AnnMoncunill Piñas, GemmaCasellas, AinaCarmona Torre, FranciscoGiráldez, MiriamSchwartz Mota, JuanaYuste, José R.Azanza, José RamónFernández, MiriamReina, GabrielDobaño, Carlota, 1969-Brew, JoeSadaba, BelenHammann, FelixRabinovich, Regina2021-03-012021-03-012020-06-081745-6215https://hdl.handle.net/2445/174448Objectives: The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test from nasopharyngeal swab at day 7 post-treatment.4 p.application/pdfengcc by (c) Chaccour et al., 2020http://creativecommons.org/licenses/by/3.0/es/SARS-CoV-2Medicaments antivíricsSARS-CoV-2Antiviral agentsThe SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trialinfo:eu-repo/semantics/article2021-02-26info:eu-repo/semantics/openAccess32513289